For U.S. Healthcare Professionals Only Sanofi Genzyme

The only microtubule inhibitor approved in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimen.

JEVTANA is a NCCN designated Category 1 Second-line Therapy1,2

A Novel Taxane With a Unique Chemical Structure2



The Novel Structure of JEVTANA Demonstrates Its Pharmacodynamic Properties at the Cellular Level2

In vitro, JEVTANA is a substrate of P-gp (P-glycoprotein), but with a low affinity. JEVTANA is not a substrate of:

  • Efflux pumps MRP1 (multidrug-resistance protein 1), MRP2 (multidrug-resistance protein 2), BCRP (breast cancer resistance protein).
  • SLC transporters OCT1 (organic cation transporter), OATP1B1 or OATP1B3 (organic anion transporting polypeptides).

IMPORTANT SAFETY INFORMATION

WARNING: NEUTROPENIA AND HYPERSENSITIVITY

  • Neutropenic deaths have been reported. Obtain frequent blood counts to monitor for neutropenia. JEVTANA is contraindicated in patients with neutrophil counts of ≤1,500 cells/mm3. Primary prophylaxis with G-CSF is recommended in patients with high-risk clinical features.
  • Severe hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm. Severe hypersensitivity reactions require immediate discontinuation of the JEVTANA infusion and administration of appropriate therapy. Patients should receive premedication. JEVTANA is contraindicated in patients who have a history of severe hypersensitivity reactions to cabazitaxel or to other drugs formulated with polysorbate 80.

You are about to leave jevtanapro.com


You are leaving jevtanapro.com to view another Sanofi Genzyme Corporation website.



Continue 
Cancel